Alternating Current-Electric Field Inducing Chorio Allantoic Membrane (CAM) Angiogenesis through Exogenous Growth Factor Intervention

This study explores a fascinating new way to promote the formation of new blood vessels, which is crucial for healing and recovery in many medical conditions. Scientists used a special device to create tiny electric fields and combined it with a natural growth substance called basic fibroblast growth factor (bFGF) in a chick embryo model. They found that while the electric fields alone didn’t do much, the combination with bFGF led to a significant increase in new blood vessel growth. This breakthrough could lead to new treatments for conditions like heart disease, where improving blood flow is essential, and certain cancers, where controlling blood vessel growth is crucial. This research shows how innovative technologies can work together with natural processes to improve health and recovery.

Key Findings:

1. No Impact on Normal Angiogenesis: AC-EF exposure did not significantly affect angiogenesis in non-bFGF-induced groups (NINT and NIT), indicating that intermediate-frequency AC-EF at 150 kHz and 18 Vpp is safe for normal physiological processes.
2. Enhanced Angiogenesis with bFGF: Significant promotion of angiogenesis was observed in the bFGF-induced AC-EF group (IT), suggesting a synergistic effect of bFGF induction and AC-EF treatment.
3. Highest Number of New Blood Vessels: The IT group, which received both bFGF induction and AC-EF treatment, exhibited the highest number of new blood vessels (36.67±10.48) and the highest angiogenesis response (51.95±43.04%), significantly more than other groups (P<0.05).
4. Statistical Significance: The IT group’s increase in new blood vessels was statistically significant compared to the other groups, as indicated by different superscript letters in the analysis.
5. VEGFA Gene Expression: No significant upregulation of VEGFA gene expression was observed in the NIT group (non-bFGF-induced, AC-EF exposure), indicating that AC-EF alone does not significantly alter VEGFA expression. Slight, but not statistically significant, upregulation of VEGFA was observed in the IT group (bFGF-induced, AC-EF exposure), suggesting that other factors might also contribute to the enhanced angiogenic response.
6. Safety of AC-EF: The lack of effect on normal angiogenesis in non-bFGF-induced groups supports the safety profile of AC-EF for clinical applications, ensuring no adverse effects on healthy tissue.
7. Therapeutic Potential: The enhanced angiogenic response in the IT group highlights the potential of AC-EF combined with growth factors like bFGF for therapeutic strategies aimed at promoting vascular growth in conditions such as chronic wounds, ischemic tissues, and certain cardiovascular diseases.
8. Context-Dependent Effects of AC-EF: The study demonstrates that the presence of exogenous growth factors like bFGF is crucial in determining the pro-angiogenic effect of AC-EF, contrasting with previous findings of AC-EF’s anti-angiogenic effects in other contexts.
9. Implications for Regenerative Medicine: The findings suggest potential applications of AC-EF in regenerative medicine, such as wound healing and the treatment of ischemic conditions, by promoting tissue repair and regeneration.